As Africa continues to experience the most severe Ebola outbreak in the disease's short history, the World Health Organization has deemed it ethical to offer unregistered interventions as potential treatments or preventive therapies, including investigational vaccines.
The U.S. National Institutes of Health is set to begin an early-stage clinical trial for an Ebola vaccine in September, according to reports.
Although GlaxoSmithKline has submitted its malaria vaccine to the European Medicines Agency for approval, the jab hasn't shown as much promise as hoped, underscoring the need for a better understanding of the malaria parasite and how it affects the human immune system.
It's taken 30 years, but GlaxoSmithKline's experimental malaria vaccine is finally ready for regulatory review. Looking to bring the world's first shot for the mosquito-borne disease to market, the pharma giant said Thursday that it has submitted its candidate for approval.
The discovery of vials of "variola," commonly known as smallpox, in a storage room at the National Institutes of Health in Bethesda, MD, has raised new concerns that the virus could be used in a bioterrorism attack.
International debate is brewing over whether to give experimental vaccines to people in regions of the current Ebola outbreak in West Africa in an effort to thwart the spread of the deadly virus.
After hitting its primary endpoint in a Phase II study last fall, Agenus was already leading a Sanofi-NIH collaboration in efforts to develop the first genital herpes vaccine. Now, it's built on that lead with new Phase II results for its therapeutic candidate, HerpV, which achieved statistical significance in reducing viral load.
Chikungunya fever is a dangerous tropical virus that has recently surfaced in the U.S. after erupting in the Caribbean. But Austria-based Themis Bioscience may eventually have a way to combat it, new data suggest.
The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.
Two doses of the oral cholera vaccine Shanchol provided an 86% percent protection rate during a recent outbreak in Guinea, according to a new study.